

STATEMENT UNDER 37 CFR 3.73(b)

Atty. Docket No. 2584.0300001/RWE/GER

Applicant/Patent Owner: HORMANN, Robert Eugene

Application No./Patent No.: 7,304,162

Filed/Issue Date: December 4, 2007

Titled: Oxadiazolone Ligands for Modulating The Expression of Exogenous Genes Via An Ecdysone Receptor Complex

Intrexon Corporation

, a

Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
- the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Rohm and Haas Company

To: RGH LLC

The document was recorded in the United States Patent and Trademark Office at

Reel 019155, Frame 0964, or for which a copy thereof is attached.

2. From: RGH LLC

To: New Rheogene LLC

The document was recorded in the United States Patent and Trademark Office at

Reel 019157, Frame 0310, or for which a copy thereof is attached.

3. From: HORMANN, Robert E. et al.

To: Rohm and Haas Company

The document was recorded in the United States Patent and Trademark Office at

Reel 019152, Frame 0810, or for which a copy thereof is attached.


- ☒ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature



Date

May 6, 2009

Grant E. Reed, Reg. No. 41,264

Printed or Typed Name

Attorney for Applicants

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**Statement Under 37 CFR 3.73(b) (PTO/SB/96)
Supplemental Sheet for Chain of Title, Item B**

Applicant/Owner: HORMANN, Robert Eugene

Application No./Patent No.: 7,304,162

Application Date/Issue Date: December 4, 2007

Title: **Oxadiazoline Ligands for Modulating The Expression of Exogenous Genes Via An Ecdysone Receptor Complex**

Name of Assignee: **Intrexon Corporation**

Type of Assignee: **Corporation**

Part B Continued: Additional Documents in the Chain of Title

4. From: New Rheogene I, LLC To: University of Pittsburgh Medical Center
The document was recorded in the United States Patent and Trademark Office at
Reel 019132, Frame 0925, or for which a copy thereof is attached.

5. From: University of Pittsburgh Medical Center To: Rheogene Holdings, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 019138, Frame 0729, or for which a copy thereof is attached.

6. From: Rheogene Holdings, Inc. To: Rheogene, Inc. (DE Corporation)
The document was recorded in the United States Patent and Trademark Office at
Reel 022473, Frame 0642, or for which a copy thereof is attached.

7. From: Rheogene, Inc. (DE Corporation) To: Intrexon Corporation
The document was recorded in the United States Patent and Trademark Office at
Reel 019150, Frame 0044, or for which a copy thereof is attached.